Publications 2023

Bramness JG, Syse A, Rognli EB (2023)
[Not Available]
Tidsskr Nor Laegeforen, 143 (3)
DOI 10.4045/tidsskr.22.0762, PubMed 36811432

Næss O, Ekeland TJ, Arnevik EA, Aarstad J, Lid TG (2023)
Governing by commissioning services - Implementing alcohol screening and brief interventions in hospital settings in Norway
Eval Program Plann, 98, 102271
DOI 10.1016/j.evalprogplan.2023.102271, PubMed 36921405

Rognli EB, Dalsrud MK, Wüsthoff LEC, Arnevik EA (2023)
[Not Available]
Tidsskr Nor Laegeforen, 143 (5)
DOI 10.4045/tidsskr.22.0471, PubMed 36987889

Rognli EB, Heiberg IH, Jacobsen BK, Høye A, Bramness JG (2023)
Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder
Am J Psychiatry, 180 (6), 437-444
DOI 10.1176/appi.ajp.22010076, PubMed 37132221

Publications 2022

Bolstad I, Alakokkare AE, Bramness JG, Rognli EB, Levola J, Mustonen A, Miettunen J, Niemelä S (2022)
The relationships between use of alcohol, tobacco and coffee in adolescence and mood disorders in adulthood
Acta Psychiatr Scand, 146 (6), 594-603
DOI 10.1111/acps.13506, PubMed 36177725

Bukten A, Lokdam NT, Skjærvø I, Ugelvik T, Skurtveit S, Gabrhelík R, Skardhamar T, Lund IO, Havnes IA, Rognli EB, Chang Z, Fazel S, Friestad C, Hesse M, Lothe J, Ploeg G, Dirkzwager AJE, Clausen T, Tjagvad C, Stavseth MR (2022)
PriSUD-Nordic-Diagnosing and Treating Substance Use Disorders in the Prison Population: Protocol for a Mixed Methods Study
JMIR Res Protoc, 11 (3), e35182
DOI 10.2196/35182, PubMed 35320114

Bækkelund H, Ulvenes P, Boon-Langelaan S, Arnevik EA (2022)
Group treatment for complex dissociative disorders: a randomized clinical trial
BMC Psychiatry, 22 (1), 338
DOI 10.1186/s12888-022-03970-8, PubMed 35578194

Edvardsen HME, Aamodt C, Bogstrand ST, Krajci P, Vindenes V, Rognli EB (2022)
Concentrations of psychoactive substances in blood samples from non-fatal and fatal opioid overdoses
Br J Clin Pharmacol, 88 (10), 4494-4504
DOI 10.1111/bcp.15365, PubMed 35470456

Rognli EB, Støme LN, Kværner KJ, Wilhelmsen C, Arnevik EA (2022)
The effect of employment support integrated in substance use treatment: A health economic cost-effectiveness simulation of three different interventions
Nordisk Alkohol Nark, 40 (2), 199-211
DOI 10.1177/14550725221122196, PubMed 37063816

Rognli EB, Taipale H, Hjorthøj C, Mittendorfer-Rutz E, Bramness JG, Heiberg IH, Niemelä S (2022)
Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016
Psychol Med, 1-10 (in press)
DOI 10.1017/S003329172200229X, PubMed 35983644

Zahl KE, Pedersen G, Eikenaes IU, Stänicke LI, Wilberg T, Baltzersen ÅL, Pettersen MS, Hummelen B, Arnevik E, Johansen MS, Hartveit Kvarstein E (2022)
Avoidant and borderline personality disorder patients during the first Covid-19 wave in Norway - a survey-based comparison of therapy changes and patients' accommodations
Nord J Psychiatry, 77 (4), 336-344
DOI 10.1080/08039488.2022.2110614, PubMed 35984379

Publications 2021

Bækkelund H, Karlsrud I, Hoffart A, Arnevik EA (2021)
Stabilizing group treatment for childhood-abuse related PTSD: a randomized controlled trial
Eur J Psychotraumatol, 12 (1), 1859079
DOI 10.1080/20008198.2020.1859079, PubMed 33537118

Kvarstein EH, Zahl KE, Stänicke LI, Pettersen MS, Baltzersen ÅL, Johansen MS, Eikenaes IU, Arnevik EA, Hummelen B, Wilberg T, Pedersen G (2021)
Vulnerability of personality disorder during the Covid-19 crises - a multicenter survey of treatment experiences among patients referred to treatment
Nord J Psychiatry, 76 (1), 52-63
DOI 10.1080/08039488.2021.1934110, PubMed 34126854

Rognli EB, Bramness JG, von Soest T (2021)
Smoking in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, antidepressants and anxiolytics
Psychol Med, 52 (14), 3241-3250
DOI 10.1017/S0033291720005401, PubMed 33583454

Rognli EB, Aas EM, Drake RE, Marsden J, Anders P, Bond GR, Lystad JU, Reme SE, Arnevik EA (2021)
The effect evaluation of Individual Placement and Support (IPS) for patients with substance use disorders: study protocol for a randomized controlled trial of IPS versus enhanced self-help
Trials, 22 (1), 705
DOI 10.1186/s13063-021-05673-z, PubMed 34654464

Publications 2020

Brorson HH, Arnevik EA, Rand-Hendriksen K, Duckert F (2020)
Corrigendum to "Drop-out from addiction treatment: A systematic review of risk factors"
Clin Psychol Rev, 76, 101796
DOI 10.1016/j.cpr.2019.101796, PubMed 32067823

Bukten A, Lund IO, Kinner SA, Rognli EB, Havnes IA, Muller AE, Stavseth MR (2020)
Factors associated with drug use in prison - results from the Norwegian offender mental health and addiction (NorMA) study
Health Justice, 8 (1), 10
DOI 10.1186/s40352-020-00112-8, PubMed 32399643

Gatti F, Walderhaug E, Kern-Godal A, Lysell J, Arnevik EA (2020)
Complementary horse-assisted therapy for substance use disorders: a randomized controlled trial
Addict Sci Clin Pract, 15 (1), 7
DOI 10.1186/s13722-020-0183-z, PubMed 32019584

Havnes IA, Bukten A, Rognli EB, Muller AE (2020)
Use of anabolic-androgenic steroids and other substances prior to and during imprisonment - Results from the Norwegian Offender Mental Health and Addiction (NorMA) study
Drug Alcohol Depend, 217, 108255
DOI 10.1016/j.drugalcdep.2020.108255, PubMed 32949884

Krackhardt F, Kočka V, Waliszewski M, Toušek P, Janek B, Trenčan M, Krajči P, Lozano F, Roman KG, Otaegui I, Del Blanco BG, Del Olmo VV, Nofrerías EF, Wachowiak L, Heang TM, Ahn TH, Jeong MH, Jung BC, Han KR, Piot C, Sebagh L, Rischner J, Pansieri M, Leschke M (2020)
Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice
Medicine (Baltimore), 99 (8), e19119
DOI 10.1097/MD.0000000000019119, PubMed 32080086

Krackhardt F, Waliszewski M, Wan Ahmad WA, Kočka V, Toušek P, Janek B, Trenčan M, Krajči P, Lozano F, Garcia-San Roman K, Otaegui Irurueta I, Garcia Del Blanco B, Wachowiak L, Vilalta Del Olmo V, Fernandez Nofrerías E, Ho Jeong M, Jung BC, Han KR, Piot C, Sebagh L, Rischner J, Pansieri M, Leschke M, Ahn TH (2020)
Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes
PLoS One, 15 (1), e0226606
DOI 10.1371/journal.pone.0226606, PubMed 31929543

Paap MCS, Hummelen B, Braeken J, Arnevik EA, Walderhaug E, Wilberg T, Berghuis H, Hutsebaut J, Pedersen G (2020)
A multi-center psychometric evaluation of the Severity Indices of Personality Problems 118 (SIPP-118): Do we really need all those facets?
Qual Life Res, 30 (2), 567-575
DOI 10.1007/s11136-020-02654-8, PubMed 33029679

Rand K, Arnevik EA, Walderhaug E (2020)
Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L
J Patient Rep Outcomes, 4 (1), 92
DOI 10.1186/s41687-020-00247-0, PubMed 33165764

Solli KK, Opheim A, Latif ZE, Krajci P, Benth JŠ, Kunoe N, Tanum L (2020)
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone
Addiction, 116 (8), 2084-2093
DOI 10.1111/add.15378, PubMed 33338285

Tonga JB, Eilertsen DE, Solem IKL, Arnevik EA, Korsnes MS, Ulstein ID (2020)
Effect of Self-Efficacy on Quality of Life in People With Mild Cognitive Impairment and Mild Dementia: The Mediating Roles of Depression and Anxiety
Am J Alzheimers Dis Other Demen, 35, 1533317519885264
DOI 10.1177/1533317519885264, PubMed 31916847

Tonga JB, Šaltytė Benth J, Arnevik EA, Werheid K, Korsnes MS, Ulstein ID (2020)
Managing depressive symptoms in people with mild cognitive impairment and mild dementia with a multicomponent psychotherapy intervention: a randomized controlled trial
Int Psychogeriatr, 33 (3), 217-231
DOI 10.1017/S1041610220000216, PubMed 32131911

Publications 2019

Arnevik EA, Pedersen G, Walderhaug E, Lien I, Wilberg T, Hummelen B (2019)
Measuring Personality Problems in Patients With Substance Use Disorders: A Cross-Sample Validation
J Dual Diagn, 15 (4), 324-332
DOI 10.1080/15504263.2019.1668583, PubMed 31571533

Brorson HH, Arnevik EA, Rand K (2019)
Predicting Dropout from Inpatient Substance Use Disorder Treatment: A Prospective Validation Study of the OQ-Analyst
Subst Abuse, 13, 1178221819866181
DOI 10.1177/1178221819866181, PubMed 31452601

Hauger LE, Sagoe D, Vaskinn A, Arnevik EA, Leknes S, Jørstad ML, Bjørnebekk A (2019)
Anabolic androgenic steroid dependence is associated with impaired emotion recognition
Psychopharmacology (Berl), 236 (9), 2667-2676
DOI 10.1007/s00213-019-05239-7, PubMed 30941469

Helverschou SB, Brunvold AR, Arnevik EA (2019)
Treating Patients With Co-occurring Autism Spectrum Disorder and Substance Use Disorder: A Clinical Explorative Study
Subst Abuse, 13, 1178221819843291
DOI 10.1177/1178221819843291, PubMed 31024216

Latif ZE, Šaltyte Benth J, Solli KK, Opheim A, Kunoe N, Krajci P, Sharma-Haase K, Tanum L (2019)
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study
JAMA Psychiatry, 76 (2), 127-134
DOI 10.1001/jamapsychiatry.2018.3537, PubMed 30566177

Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci P, Sharma-Haase K, Tanum L (2019)
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study
Am J Addict, 28 (2), 77-85
DOI 10.1111/ajad.12859, PubMed 30701613

Pedersen G, Arnevik EA, Hummelen B, Walderhaug E, Wilberg T (2019)
Psychometric Properties of the Severity Indices of Personality Problems (SIPP) in Two Samples A Norwegian Community Sample and Clinical Samples of Patients With and Without Personality Disorders
Eur. J. Psychol. Assess., 35 (5), 698-711
DOI 10.1027/1015-5759/a000436

Rognli EB, Bramness JG, von Soest T (2019)
Cannabis use in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, and antidepressants
Acta Psychiatr Scand, 141 (2), 149-156
DOI 10.1111/acps.13104, PubMed 31560790

Solli KK, Kunoe N, Latif ZE, Sharma-Haase K, Opheim A, Krajci P, Gaulen Z, Šaltytė Benth J, Tanum L (2019)
Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial
Eur Addict Res, 25 (6), 303-309
DOI 10.1159/000501931, PubMed 31340204

Sømhovd M, Hagen E, Bergly T, Arnevik EA (2019)
The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment
Heliyon, 5 (3), e01282
DOI 10.1016/j.heliyon.2019.e01282, PubMed 31025003

Publications 2018

Bækkelund H, Frewen P, Lanius R, Ottesen Berg A, Arnevik EA (2018)
Trauma-related altered states of consciousness in post-traumatic stress disorder patients with or without comorbid dissociative disorders
Eur J Psychotraumatol, 9 (1), 1544025
DOI 10.1080/20008198.2018.1544025, PubMed 30455853

Hagen E, Sømhovd M, Hesse M, Arnevik EA, Erga AH (2018)
Measuring cognitive impairment in young adults with polysubstance use disorder with MoCA or BRIEF-A - The significance of psychiatric symptoms
J Subst Abuse Treat, 97, 21-27
DOI 10.1016/j.jsat.2018.11.010, PubMed 30577896

Henriksen K, Jacobsen JA, Henriksen EM, Gomes L, Waal H, Krajci P (2018)
The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting
Eur Addict Res, 24 (6), 286-292
DOI 10.1159/000495188, PubMed 30466108

Muller AE, Havnes IA, Rognli EB, Bukten A (2018)
Inmates with Harmful Substance Use Increase Both Exercise and Nicotine Use Under Incarceration
Int J Environ Res Public Health, 15 (12)
DOI 10.3390/ijerph15122663, PubMed 30486386

Ringen PA, Faerden A, Antonsen B, Falk RS, Mamen A, Rognli EB, Solberg DK, Andreassen OA, Martinsen EW (2018)
Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments
Nord J Psychiatry, 72 (4), 296-302
DOI 10.1080/08039488.2018.1449012, PubMed 29523041

Ringen PA, Falk RS, Antonsen B, Faerden A, Mamen A, Rognli EB, Solberg DK, Martinsen EW, Andreassen OA (2018)
Using motivational techniques to reduce cardiometabolic risk factors in long term psychiatric inpatients: a naturalistic interventional study
BMC Psychiatry, 18 (1), 255
DOI 10.1186/s12888-018-1832-6, PubMed 30111298

Solli KK, Latif ZE, Opheim A, Krajci P, Sharma-Haase K, Benth JŠ, Tanum L, Kunoe N (2018)
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial
Addiction, 113 (10), 1840-1849
DOI 10.1111/add.14278, PubMed 29806872

Publications 2017

Krajči P, Kirnbauer R, Parajka J, Schöber J, Blöschl G (2017)
The Kühtai data set: 25 years of lysimetric, snow pillow, and meteorological measurements
Water Resour Res, 53 (6), 5158-5165
DOI 10.1002/2017WR020445, PubMed 28931957

Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N (2017)
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial
JAMA Psychiatry, 74 (12), 1197-1205
DOI 10.1001/jamapsychiatry.2017.3206, PubMed 29049469

Wright N, Reimer J, Somaini L, Roncero C, Maremmani I, Simon N, Krajci P, Littlewood R, D'Agnone O, Alho H, Rolland B (2017)
Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model
Eur J Gastroenterol Hepatol, 29 (11), 1206-1214
DOI 10.1097/MEG.0000000000000962, PubMed 28914697

Publications 2016

Arnevik EA, Helverschou SB (2016)
Autism Spectrum Disorder and Co-occurring Substance Use Disorder - A Systematic Review
Subst Abuse, 10, 69-75
DOI 10.4137/SART.S39921, PubMed 27559296

Bramness JG, Rognli EB (2016)
Psychosis induced by amphetamines
Curr Opin Psychiatry, 29 (4), 236-41
DOI 10.1097/YCO.0000000000000254, PubMed 27175554

Henriksen K, Waal H, Krajci P (2016)
Will non-compliant 'hard-to-treat' opioid-dependent patients profit from low threshold methadone treatment? A prospective 15-month evaluation of patients on Low Dosage Methadone treatment at Oslo University Hospital
Heroin Addict. Relat. Clin. Probl., 18 (3), 23-27

Kern-Godal A, Brenna IH, Arnevik EA, Ravndal E (2016)
More Than Just a Break from Treatment: How Substance Use Disorder Patients Experience the Stable Environment in Horse-Assisted Therapy
Subst Abuse, 10, 99-108
DOI 10.4137/SART.S40475, PubMed 27746677

Kern-Godal A, Brenna IH, Kogstad N, Arnevik EA, Ravndal E (2016)
Contribution of the patient-horse relationship to substance use disorder treatment: Patients' experiences
Int J Qual Stud Health Well-being, 11, 31636
DOI 10.3402/qhw.v11.31636, PubMed 27291162

Lien IA, Arnevik EA (2016)
Assessment of personality problems among patients with substance use disorders
Nord. Stud. Alcohol Drugs, 33 (4), 399-414
DOI 10.1515/nsad-2016-0033

Maremmani I, Rolland B, Somaini L, Roncero C, Reimer J, Wright N, Littlewood R, Krajci P, Alho H, D'Agnone O, Simon N (2016)
Buprenorphine dosing choices in specific populations: review of expert opinion
Expert Opin Pharmacother, 17 (13), 1727-31
DOI 10.1080/14656566.2016.1209486, PubMed 27376622

Nordheim K, Walderhaug E, Alstadius S, Kern-Godal A, Arnevik E, Duckert F (2016)
Young adults' reasons for dropout from residential substance use disorder treatment
Qual Soc Work, 17 (1), 24-40
DOI 10.1177/1473325016654559, PubMed 29276430

Rognli EB, Bramness JG, Skurtveit S, Bukten A (2016)
Substance use and sociodemographic background as risk factors for lifetime psychotic experiences in a non-clinical sample
J Subst Abuse Treat, 74, 42-47
DOI 10.1016/j.jsat.2016.12.007, PubMed 28132699

Publications 2015

Alho H, D'Agnone O, Krajci P, McKeganey N, Maremmani I, Reimer J, Roncero C, Somaini L, Wright N, Littlewood R (2015)
The extent of misuse and diversion of medication for agonist opioid treatment: A review and expert opinions
Heroin Addict. Relat. Clin. Probl., 17 (2-3), 25-33

Alho H, Jansen J, Krajci P, Littlewood R, Runarsdottir V, Nyberg F (2015)
Misuse and diversion of agonist opioid treatment medicines: assessment of the scale of the problem and review of the changing environment for care in the Nordic countries
Heroin Addict. Relat. Clin. Probl., 17 (5), 43-49

Bukten A, Lund IO, Rognli EB, Stavseth MR, Lobmaier P, Skurtveit S, Clausen T, Kunøe N (2015)
The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study
Subst Abuse, 9 (Suppl 2), 59-66
DOI 10.4137/SaRt.S23546, PubMed 26648732

Kern-Godal A, Arnevik EA, Walderhaug E, Ravndal E (2015)
Substance use disorder treatment retention and completion: a prospective study of horse-assisted therapy (HAT) for young adults
Addict Sci Clin Pract, 10, 21
DOI 10.1186/s13722-015-0043-4, PubMed 26466788

Medhus S, Rognli EB, Gossop M, Holm B, Mørland J, Bramness JG (2015)
Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample
Am J Addict, 24 (7), 586-9
DOI 10.1111/ajad.12274, PubMed 26332037

Opdal MS, Arnesen M, Müller LD, Hullstein I, Sayed K, Brørs O, Kringen M, Sagedal S, Gjesdal K, Krajci P (2015)
Effects of Hemodialysis on Methadone Pharmacokinetics and QTc
Clin Ther, 37 (7), 1594-9
DOI 10.1016/j.clinthera.2015.04.009, PubMed 25963997

Reimer J, Wright N, Somaini L, Roncero C, Maremmani I, McKeganey N, Littlewood R, Krajci P, Alho H, D'Agnone O (2015)
The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus
Eur Addict Res, 22 (2), 99-106
DOI 10.1159/000438988, PubMed 26426530

Rognli EB, Berge J, Håkansson A, Bramness JG (2015)
Long-term risk factors for substance-induced and primary psychosis after release from prison. A longitudinal study of substance users
Schizophr Res, 168 (1-2), 185-90
DOI 10.1016/j.schres.2015.08.032, PubMed 26359848

Rognli EB, Medhus SE, Bramness JG (2015)
[Amphetamine-induced psychosis or schizophrenia?]
Tidsskr Nor Laegeforen, 135 (3), 249-51
DOI 10.4045/tidsskr.14.1365, PubMed 25668544

Tonga JB, Arnevik EA, Werheid K, Ulstein ID (2015)
Manual-based cognitive behavioral and cognitive rehabilitation therapy for young-onset dementia: a case report
Int Psychogeriatr, 28 (3), 519-22
DOI 10.1017/S1041610215001696, PubMed 26552831

Tonga JB, Karlsoeen BB, Arnevik EA, Werheid K, Korsnes MS, Ulstein ID (2015)
Challenges With Manual-Based Multimodal Psychotherapy for People With Alzheimer's Disease: A Case Study
Am J Alzheimers Dis Other Demen, 31 (4), 311-7
DOI 10.1177/1533317515603958, PubMed 26385947

Wright N, D'Agnone O, Krajci P, Littlewood R, Alho H, Reimer J, Roncero C, Somaini L, Maremmani I (2015)
Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience
J Public Health (Oxf), 38 (3), e368-e374
DOI 10.1093/pubmed/fdv150, PubMed 26508767

Publications 2014

Rognli EB, Håkansson A, Berge J, Bramness JG (2014)
Does the pattern of amphetamine use prior to incarceration predict later psychosis?--a longitudinal study of amphetamine users in the Swedish criminal justice system
Drug Alcohol Depend, 143, 219-24
DOI 10.1016/j.drugalcdep.2014.07.037, PubMed 25146382

Publications 2013

Amble I, Gude T, Stubdal S, Oktedalen T, Skjorten AM, Andersen BJ, Solbakken OA, Brorson HH, Arnevik E, Lambert MJ, Wampold BE (2013)
Psychometric properties of the outcome questionnaire-45.2: the Norwegian version in an international context
Psychother Res, 24 (4), 504-13
DOI 10.1080/10503307.2013.849016, PubMed 24188797

Kvarstein EH, Arnevik E, Halsteinli V, Rø FG, Karterud S, Wilberg T (2013)
Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice
BMC Psychiatry, 13, 315
DOI 10.1186/1471-244X-13-315, PubMed 24268099

Publications 2012

Bramness JG, Gundersen ØH, Guterstam J, Rognli EB, Konstenius M, Løberg EM, Medhus S, Tanum L, Franck J (2012)
Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?
BMC Psychiatry, 12, 221
DOI 10.1186/1471-244X-12-221, PubMed 23216941

Publications 2010

Arnevik E, Wilberg T, Urnes Ø, Johansen M, Monsen JT, Karterud S (2010)
Psychotherapy for personality disorders: 18 months' follow-up of the ullevål personality project
J Pers Disord, 24 (2), 188-203
DOI 10.1521/pedi.2010.24.2.188, PubMed 20420475

Publications 2009

Arnevik E, Wilberg T, Monsen JT, Andrea H, Karterud S (2009)
A cross-national validity study of the Severity Indices of Personality Problems (SIPP-118)
Personal. Ment. Health, 3 (1), 41-55
DOI 10.1002/pmh.60

Publications 2008

Arnevik E, Wilberg T, Urnes O, Johansen M, Monsen JT, Karterud S (2008)
Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study
Eur Psychiatry, 24 (2), 71-8
DOI 10.1016/j.eurpsy.2008.09.004, PubMed 19097870

Publications 2005

Vermund H, Krajci P, Eide TJ, Winther F (2005)
Histopathological grading of laryngectomy specimens
APMIS, 113 (7-8), 473-88
DOI 10.1111/j.1600-0463.2005.apm_24.x, PubMed 16086817

Publications 2004

Vermund H, Krajci P, Eide TJ, Winther F (2004)
Laryngectomy whole organ serial sections--histological parameters correlated with recurrence rate
Acta Oncol, 43 (1), 98-107
DOI 10.1080/02841860310020366, PubMed 15068327

Publications 2002

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
N Engl J Med, 346 (25), 1937-47
DOI 10.1056/NEJMoa012914, PubMed 12075054

Publications 2000

Wiatrowska B, Krajci P, Berner A (2000)
[Pseudo-Meigs' syndrome]
Tidsskr Nor Laegeforen, 120 (3), 364-6
PubMed 10827530

Publications 1999

Johansen FE, Pekna M, Norderhaug IN, Haneberg B, Hietala MA, Krajci P, Betsholtz C, Brandtzaeg P (1999)
Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice
J Exp Med, 190 (7), 915-22
DOI 10.1084/jem.190.7.915, PubMed 10510081

Nilsen EM, Johansen FE, Kvale D, Krajci P, Brandtzaeg P (1999)
Different regulatory pathways employed in cytokine-enhanced expression of secretory component and epithelial HLA class I genes
Eur J Immunol, 29 (1), 168-79
DOI 10.1002/(SICI)1521-4141(199901)29:01<168::AID-IMMU168>3.0.CO;2-8, PubMed 9933098

Norderhaug IN, Johansen FE, Krajci P, Brandtzaeg P (1999)
Domain deletions in the human polymeric Ig receptor disclose differences between its dimeric IgA and pentameric IgM interaction
Eur J Immunol, 29 (10), 3401-9
DOI 10.1002/(SICI)1521-4141(199910)29:10<3401::AID-IMMU3401>3.0.CO;2-G, PubMed 10540352

Publications 1998

Johansen FE, Bosløven BA, Krajci P, Brandtzaeg P (1998)
A composite DNA element in the promoter of the polymeric immunoglobulin receptor regulates its constitutive expression
Eur J Immunol, 28 (4), 1161-71
DOI 10.1002/(SICI)1521-4141(199804)28:04<1161::AID-IMMU1161>3.0.CO;2-S, PubMed 9565355

Publications 1997

Winberg JO, Hammami-Hauasli N, Nilssen O, Anton-Lamprecht I, Naylor SL, Kerbacher K, Zimmermann M, Krajci P, Gedde-Dahl T, Bruckner-Tuderman L (1997)
Modulation of disease severity of dystrophic epidermolysis bullosa by a splice site mutation in combination with a missense mutation in the COL7A1 gene
Hum Mol Genet, 6 (7), 1125-35
DOI 10.1093/hmg/6.7.1125, PubMed 9215684

Publications 1996

Krajci P, Meling GI, Andersen SN, Hofstad B, Vatn MH, Rognum TO, Brandtzaeg P (1996)
Secretory component mRNA and protein expression in colorectal adenomas and carcinomas
Br J Cancer, 73 (12), 1503-10
DOI 10.1038/bjc.1996.284, PubMed 8664120

Publications 1995

Brandtzaeg P, Krajci P (1995)
The enterocyte and immunoglobulin transport
Dyn.Nutr.Res., 4, 1-17

Kamei M, Iwase T, Krajci P, Brandtzaeg P, Moro I (1995)
Antibody production to secretory component (SC) using recombinant SC fragment
Adv Exp Med Biol, 371A, 633-5
DOI 10.1007/978-1-4615-1941-6_133, PubMed 8526006

Krajci P, Kvale D, Brandtzaeg P (1995)
Cloning, chromosomal localization, and linkage analysis of the gene encoding human transmembrane secretory component (the poly-Ig receptor)
Adv Exp Med Biol, 371A, 617-23
DOI 10.1007/978-1-4615-1941-6_130, PubMed 8526003

Kulseth MA, Krajci P, Myklebost O, Rogne S (1995)
Cloning and characterization of two forms of bovine polymeric immunoglobulin receptor cDNA
DNA Cell Biol, 14 (3), 251-6
DOI 10.1089/dna.1995.14.251, PubMed 7880445

Moro I, Takahashi T, Iwase T, Asano M, Takenouchi N, Nishimura S, Kudo I, Krajci P, Brandtzaeg P, Moldoveanu Z (1995)
Expression of SC, IL-6 and TGF-beta 1 in epithelial cell lines
Adv Exp Med Biol, 371A, 175-82
DOI 10.1007/978-1-4615-1941-6_36, PubMed 8525901

Nilsen EM, Lundin KE, Krajci P, Scott H, Sollid LM, Brandtzaeg P (1995)
Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma
Gut, 37 (6), 766-76
DOI 10.1136/gut.37.6.766, PubMed 8537046

Norstein J, Krajci P, Bergan A, Geiran O (1995)
Intestinal perforation after ingestion of a blister-wrapped tablet
Lancet, 346 (8985), 1308
DOI 10.1016/s0140-6736(95)91918-x, PubMed 7475762

Publications 1993

Krajci P, Taskén K, Kvale D, Brandtzaeg P (1993)
Interferon-gamma stimulation of messenger RNA for human secretory component (poly-Ig receptor) depends on continuous intermediate protein synthesis
Scand J Immunol, 37 (2), 251-6
DOI 10.1111/j.1365-3083.1993.tb01763.x, PubMed 8434236

Publications 1992

Brandtzaeg P, Halstensen TS, Huitfeldt HS, Krajci P, Kvale D, Scott H, Thrane PS (1992)
Epithelial expression of HLA, secretory component (poly-Ig receptor), and adhesion molecules in the human alimentary tract
Ann N Y Acad Sci, 664, 157-79
DOI 10.1111/j.1749-6632.1992.tb39758.x, PubMed 1456647

BRANDTZAEG P, HALSTENSEN TS, HUITFELDT HS, KRAJCI P, KVALE D, SCOTT H, THRANE PS (1992)
EPITHELIAL EXPRESSION OF HLA, SECRETORY COMPONENT (POLY-IG RECEPTOR), AND ADHESION MOLECULES IN THE HUMAN ALIMENTARY-TRACT
Ann.NY Acad.Sci., 664, 157-179
DOI 10.1111/j.1749-6632.1992.tb39758.x

Krajci P, Gedde-Dahl T, Høyheim B, Rogde S, Olaisen B, Brandtzaeg P (1992)
The gene encoding human transmembrane secretory component (locus PIGR) is linked to D1S58 on chromosome 1
Hum Genet, 90 (3), 215-9
DOI 10.1007/BF00220065, PubMed 1487233

Krajci P, Kvale D, Taskén K, Brandtzaeg P (1992)
Molecular cloning and exon-intron mapping of the gene encoding human transmembrane secretory component (the poly-Ig receptor)
Eur J Immunol, 22 (9), 2309-15
DOI 10.1002/eji.1830220920, PubMed 1355431

Kvale D, Krajci P, Brandtzaeg P (1992)
Expression and regulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines
Scand J Immunol, 35 (6), 669-76
DOI 10.1111/j.1365-3083.1992.tb02973.x, PubMed 1376489

Solberg R, Sistonen P, Träskelin AL, Bérubé D, Simard J, Krajci P, Jahnsen T, de la Chapelle A (1992)
Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7
Genomics, 14 (1), 63-9
DOI 10.1016/s0888-7543(05)80284-8, PubMed 1358799

Publications 1991

Krajci P, Grzeschik KH, Geurts van Kessel AH, Olaisen B, Brandtzaeg P (1991)
The human transmembrane secretory component (poly-Ig receptor): molecular cloning, restriction fragment length polymorphism and chromosomal sublocalization
Hum Genet, 87 (6), 642-8
DOI 10.1007/BF00201717, PubMed 1682231

Publications 1989

Brandtzaeg P, Halstensen TS, Kett K, Krajci P, Kvale D, Rognum TO, Scott H, Sollid LM (1989)
Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes
Gastroenterology, 97 (6), 1562-84
DOI 10.1016/0016-5085(89)90406-x, PubMed 2684725

Krajci P, Solberg R, Sandberg M, Oyen O, Jahnsen T, Brandtzaeg P (1989)
Molecular cloning of the human transmembrane secretory component (poly-Ig receptor) and its mRNA expression in human tissues
Biochem Biophys Res Commun, 158 (3), 783-9
DOI 10.1016/0006-291x(89)92790-3, PubMed 2920039

Publications 1986

Iversen OH, Krajci P, Thoresen G (1986)
The fate of epidermal colcemid-arrested mitoses
Virchows Arch B Cell Pathol Incl Mol Pathol, 51 (2), 115-26
DOI 10.1007/BF02899022, PubMed 2873676